2022-2029 Global Amyotrophic Lateral Sclerosis (ALS) Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)

Code: RW00014698890
Maia Research
Jul-2022
Life Sciences
125 Pages

The Amyotrophic Lateral Sclerosis (ALS) market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029.

The report focuses on the Amyotrophic Lateral Sclerosis (ALS) market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain.

Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Consumer behavior analysis and market dynamics (drivers, restraints, opportunities) provides crucial information for knowing the Amyotrophic Lateral Sclerosis (ALS) market.

Key players in the global Amyotrophic Lateral Sclerosis (ALS) market covered in Chapter 2 and Chapter 6:
AZTherapies
Sanofi/Covis
Biogen
Orphazyme
Samus Therapeutics
Orion Pharma
Clene Nanomedicine
Novartis Pharmaceuticals
Revalesio Corporation
Amylyx Pharmaceuticals
Gilead Sciences
Biohaven Pharmaceuticals
Novus Therapeutics
TikoMed AB/Neuregenix
Annexon
PTC Therapeutics/ Dainippon Sumitomo Pharma
Alexion Pharmaceuticals
Cytokinetics/Astellas Pharma
GlaxoSmithKline
Apellis Pharmaceuticals
Aquestive Therapeutics
Avanir Pharmaceuticals (a subsidiary of Otsuka America)
Mitsubishi Tanabe Pharma Corporation
ABC Science
MediciNova
Ionis Pharmaceuticals/Biogen
Brainstorm Cell Therapeutics
UCB Pharma
ITF Pharma (a US subsidiary Italfarmaco S.p.A.)

In Chapter 8 and Chapter 10.3, based on types, the Amyotrophic Lateral Sclerosis (ALS) market from 2017 to 2029 is primarily split into:
Riluzole
Edaravone (Radicava)
Others

In Chapter 9 and Chapter 10.4, based on applications, the Amyotrophic Lateral Sclerosis (ALS) market from 2017 to 2029 covers:
Hospital
Drugs Store
Others

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2017 -2029) of the following regions:
United States
Europe (Germany, UK, France, Italy, Spain, Russia, Poland)
China
Japan
India
Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)
Latin America (Brazil, Mexico, Colombia)
Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)
Other Regions

Chapter 1 provides an overview of Amyotrophic Lateral Sclerosis (ALS) market, containing global revenue and CAGR. The forecast and analysis of Amyotrophic Lateral Sclerosis (ALS) market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 introduces the industrial chain of Amyotrophic Lateral Sclerosis (ALS). Industrial chain analysis, raw material (suppliers, price, supply and demand, market concentration rate) and downstream buyers are analyzed in this chapter.

Chapter 4 concentrates on manufacturing analysis, including cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 5 provides clear insights into market dynamics, the influence of COVID-19 in Amyotrophic Lateral Sclerosis (ALS) industry, consumer behavior analysis.

Chapter 6 provides a full-scale analysis of major players in Amyotrophic Lateral Sclerosis (ALS) industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 7 pays attention to the sales, revenue, price and gross margin of Amyotrophic Lateral Sclerosis (ALS) in markets of different regions. The analysis on sales, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 gives a worldwide view of Amyotrophic Lateral Sclerosis (ALS) market. It includes sales, revenue, price, market share and the growth rate by type.

Chapter 9 focuses on the application of Amyotrophic Lateral Sclerosis (ALS), by analyzing the consumption and its growth rate of each application.

Chapter 10 prospects the whole Amyotrophic Lateral Sclerosis (ALS) market, including the global sales and revenue forecast, regional forecast. It also foresees the Amyotrophic Lateral Sclerosis (ALS) market by type and application.

Years considered for this report:
Historical Years: 2017-2021
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2022-2029

Table of Content

1 Amyotrophic Lateral Sclerosis (ALS) Market Overview
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
1.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales and CAGR (%) Comparison by Type (2017-2029)
1.2.2 The Market Profile of Riluzole
1.2.3 The Market Profile of Edaravone (Radicava)
1.2.4 The Market Profile of Others
1.3 Global Amyotrophic Lateral Sclerosis (ALS) Segment by Application
1.3.1 Amyotrophic Lateral Sclerosis (ALS) Consumption (Sales) Comparison by Application (2017-2029)
1.3.2 The Market Profile of Hospital
1.3.3 The Market Profile of Drugs Store
1.3.4 The Market Profile of Others
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Market, Region Wise (2017-2022)
1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size (Revenue) and CAGR (%) Comparison by Region (2017-2022)
1.4.2 United States Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.1 Germany Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.2 UK Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.3 France Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.4 Italy Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.5 Spain Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.6 Russia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.3.7 Poland Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.4 China Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.5 Japan Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.6 India Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.1 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.2 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.3 Philippines Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.4 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.5 Thailand Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.7.6 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.8 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.8.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.8.2 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.8.3 Colombia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.1 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.2 United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.3 Turkey Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.4 Egypt Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.5 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.4.9.6 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Status and Prospect (2017-2022)
1.5 Global Market Size of Amyotrophic Lateral Sclerosis (ALS) (2017-2029)
1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Status and Outlook (2017-2029)
1.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Status and Outlook (2017-2029)

2 Global Amyotrophic Lateral Sclerosis (ALS) Market Landscape by Player
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Share by Player (2017-2022)
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Player (2017-2022)
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Player (2017-2022)
2.4 Global Amyotrophic Lateral Sclerosis (ALS) Gross Margin by Player (2017-2022)
2.5 Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base Distribution, Sales Area and Product Type by Player
2.6 Amyotrophic Lateral Sclerosis (ALS) Market Competitive Situation and Trends
2.6.1 Amyotrophic Lateral Sclerosis (ALS) Market Concentration Rate
2.6.2 Amyotrophic Lateral Sclerosis (ALS) Market Share of Top 3 and Top 6 Players
2.6.3 Mergers & Acquisitions, Expansion

3 Amyotrophic Lateral Sclerosis (ALS) Upstream and Downstream Analysis
3.1 Amyotrophic Lateral Sclerosis (ALS) Industrial Chain Analysis
3.2 Key Raw Materials Suppliers and Price Analysis
3.3 Key Raw Materials Supply and Demand Analysis
3.4 Manufacturing Process Analysis
3.5 Market Concentration Rate of Raw Materials
3.6 Downstream Buyers
3.7 Value Chain Status Under COVID-19

4 Amyotrophic Lateral Sclerosis (ALS) Manufacturing Cost Analysis
4.1 Manufacturing Cost Structure Analysis
4.2 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials Cost Analysis
4.2.1 Key Raw Materials Introduction
4.2.2 Price Trend of Key Raw Materials
4.3 Labor Cost Analysis
4.3.1 Labor Cost of Amyotrophic Lateral Sclerosis (ALS) Under COVID-19
4.4 Energy Costs Analysis
4.5 R&D Costs Analysis

5 Market Dynamics
5.1 Drivers
5.2 Restraints and Challenges
5.3 Opportunities
5.3.1 Advances in Innovation and Technology for Amyotrophic Lateral Sclerosis (ALS)
5.3.2 Increased Demand in Emerging Markets
5.4 Amyotrophic Lateral Sclerosis (ALS) Industry Development Trends under COVID-19 Outbreak
5.4.1 Global COVID-19 Status Overview
5.4.2 Influence of COVID-19 Outbreak on Amyotrophic Lateral Sclerosis (ALS) Industry Development
5.5 Consumer Behavior Analysis

6 Players Profiles
6.1 AZTherapies
6.1.1 AZTherapies Basic Information, Manufacturing Base, Sales Area and Competitors
6.1.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.1.3 AZTherapies Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.1.4 AZTherapies Business Overview
6.2 Sanofi/Covis
6.2.1 Sanofi/Covis Basic Information, Manufacturing Base, Sales Area and Competitors
6.2.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.2.3 Sanofi/Covis Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.2.4 Sanofi/Covis Business Overview
6.3 Biogen
6.3.1 Biogen Basic Information, Manufacturing Base, Sales Area and Competitors
6.3.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.3.3 Biogen Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.3.4 Biogen Business Overview
6.4 Orphazyme
6.4.1 Orphazyme Basic Information, Manufacturing Base, Sales Area and Competitors
6.4.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.4.3 Orphazyme Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.4.4 Orphazyme Business Overview
6.5 Samus Therapeutics
6.5.1 Samus Therapeutics Basic Information, Manufacturing Base, Sales Area and Competitors
6.5.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.5.3 Samus Therapeutics Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.5.4 Samus Therapeutics Business Overview
6.6 Orion Pharma
6.6.1 Orion Pharma Basic Information, Manufacturing Base, Sales Area and Competitors
6.6.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.6.3 Orion Pharma Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.6.4 Orion Pharma Business Overview
6.7 Clene Nanomedicine
6.7.1 Clene Nanomedicine Basic Information, Manufacturing Base, Sales Area and Competitors
6.7.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.7.3 Clene Nanomedicine Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.7.4 Clene Nanomedicine Business Overview
6.8 Novartis Pharmaceuticals
6.8.1 Novartis Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Competitors
6.8.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.8.3 Novartis Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.8.4 Novartis Pharmaceuticals Business Overview
6.9 Revalesio Corporation
6.9.1 Revalesio Corporation Basic Information, Manufacturing Base, Sales Area and Competitors
6.9.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.9.3 Revalesio Corporation Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.9.4 Revalesio Corporation Business Overview
6.10 Amylyx Pharmaceuticals
6.10.1 Amylyx Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Competitors
6.10.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.10.3 Amylyx Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.10.4 Amylyx Pharmaceuticals Business Overview
6.11 Gilead Sciences
6.11.1 Gilead Sciences Basic Information, Manufacturing Base, Sales Area and Competitors
6.11.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.11.3 Gilead Sciences Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.11.4 Gilead Sciences Business Overview
6.12 Biohaven Pharmaceuticals
6.12.1 Biohaven Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Competitors
6.12.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.12.3 Biohaven Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.12.4 Biohaven Pharmaceuticals Business Overview
6.13 Novus Therapeutics
6.13.1 Novus Therapeutics Basic Information, Manufacturing Base, Sales Area and Competitors
6.13.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.13.3 Novus Therapeutics Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.13.4 Novus Therapeutics Business Overview
6.14 TikoMed AB/Neuregenix
6.14.1 TikoMed AB/Neuregenix Basic Information, Manufacturing Base, Sales Area and Competitors
6.14.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.14.3 TikoMed AB/Neuregenix Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.14.4 TikoMed AB/Neuregenix Business Overview
6.15 Annexon
6.15.1 Annexon Basic Information, Manufacturing Base, Sales Area and Competitors
6.15.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.15.3 Annexon Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.15.4 Annexon Business Overview
6.16 PTC Therapeutics/ Dainippon Sumitomo Pharma
6.16.1 PTC Therapeutics/ Dainippon Sumitomo Pharma Basic Information, Manufacturing Base, Sales Area and Competitors
6.16.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.16.3 PTC Therapeutics/ Dainippon Sumitomo Pharma Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.16.4 PTC Therapeutics/ Dainippon Sumitomo Pharma Business Overview
6.17 Alexion Pharmaceuticals
6.17.1 Alexion Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Competitors
6.17.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.17.3 Alexion Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.17.4 Alexion Pharmaceuticals Business Overview
6.18 Cytokinetics/Astellas Pharma
6.18.1 Cytokinetics/Astellas Pharma Basic Information, Manufacturing Base, Sales Area and Competitors
6.18.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.18.3 Cytokinetics/Astellas Pharma Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.18.4 Cytokinetics/Astellas Pharma Business Overview
6.19 GlaxoSmithKline
6.19.1 GlaxoSmithKline Basic Information, Manufacturing Base, Sales Area and Competitors
6.19.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.19.3 GlaxoSmithKline Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.19.4 GlaxoSmithKline Business Overview
6.20 Apellis Pharmaceuticals
6.20.1 Apellis Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Competitors
6.20.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.20.3 Apellis Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.20.4 Apellis Pharmaceuticals Business Overview
6.21 Aquestive Therapeutics
6.21.1 Aquestive Therapeutics Basic Information, Manufacturing Base, Sales Area and Competitors
6.21.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.21.3 Aquestive Therapeutics Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.21.4 Aquestive Therapeutics Business Overview
6.22 Avanir Pharmaceuticals (a subsidiary of Otsuka America)
6.22.1 Avanir Pharmaceuticals (a subsidiary of Otsuka America) Basic Information, Manufacturing Base, Sales Area and Competitors
6.22.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.22.3 Avanir Pharmaceuticals (a subsidiary of Otsuka America) Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.22.4 Avanir Pharmaceuticals (a subsidiary of Otsuka America) Business Overview
6.23 Mitsubishi Tanabe Pharma Corporation
6.23.1 Mitsubishi Tanabe Pharma Corporation Basic Information, Manufacturing Base, Sales Area and Competitors
6.23.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.23.3 Mitsubishi Tanabe Pharma Corporation Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.23.4 Mitsubishi Tanabe Pharma Corporation Business Overview
6.24 ABC Science
6.24.1 ABC Science Basic Information, Manufacturing Base, Sales Area and Competitors
6.24.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.24.3 ABC Science Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.24.4 ABC Science Business Overview
6.25 MediciNova
6.25.1 MediciNova Basic Information, Manufacturing Base, Sales Area and Competitors
6.25.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.25.3 MediciNova Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.25.4 MediciNova Business Overview
6.26 Ionis Pharmaceuticals/Biogen
6.26.1 Ionis Pharmaceuticals/Biogen Basic Information, Manufacturing Base, Sales Area and Competitors
6.26.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.26.3 Ionis Pharmaceuticals/Biogen Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.26.4 Ionis Pharmaceuticals/Biogen Business Overview
6.27 Brainstorm Cell Therapeutics
6.27.1 Brainstorm Cell Therapeutics Basic Information, Manufacturing Base, Sales Area and Competitors
6.27.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.27.3 Brainstorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.27.4 Brainstorm Cell Therapeutics Business Overview
6.28 UCB Pharma
6.28.1 UCB Pharma Basic Information, Manufacturing Base, Sales Area and Competitors
6.28.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.28.3 UCB Pharma Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.28.4 UCB Pharma Business Overview
6.29 ITF Pharma (a US subsidiary Italfarmaco S.p.A.)
6.29.1 ITF Pharma (a US subsidiary Italfarmaco S.p.A.) Basic Information, Manufacturing Base, Sales Area and Competitors
6.29.2 Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
6.29.3 ITF Pharma (a US subsidiary Italfarmaco S.p.A.) Amyotrophic Lateral Sclerosis (ALS) Market Performance (2017-2022)
6.29.4 ITF Pharma (a US subsidiary Italfarmaco S.p.A.) Business Overview

7 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Region Wise (2017-2022)
7.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Market Share, Region Wise (2017-2022)
7.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue (Revenue) and Market Share, Region Wise (2017-2022)
7.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.4 United States Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.4.1 United States Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.5 Europe Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.5.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.6 China Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.6.1 China Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.7 Japan Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.7.1 Japan Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.8 India Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.8.1 India Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.9 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.9.1 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.10 Latin America Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.10.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19
7.11 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
7.11.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Under COVID-19

8 Global Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue (Revenue), Price Trend by Type
8.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Market Share by Type (2017-2022)
8.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2017-2022)
8.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2017-2022)
8.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Type (2017-2022)
8.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate of Riluzole (2017-2022)
8.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate of Edaravone (Radicava) (2017-2022)
8.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate of Others (2017-2022)

9 Global Amyotrophic Lateral Sclerosis (ALS) Market Analysis by Application
9.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption and Market Share by Application (2017-2022)
9.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Growth Rate by Application (2017-2022)
9.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Growth Rate of Hospital (2017-2022)
9.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Growth Rate of Drugs Store (2017-2022)
9.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Growth Rate of Others (2017-2022)

10 Global Amyotrophic Lateral Sclerosis (ALS) Market Forecast (2022-2029)
10.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue Forecast (2022-2029)
10.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate Forecast (2022-2029)
10.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate Forecast (2022-2029)
10.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Price and Trend Forecast (2022-2029)
10.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast, Region Wise (2022-2029)
10.2.1 United States Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.3 China Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.4 Japan Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.5 India Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.7 Latin America Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.2.8 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales and Revenue Forecast (2022-2029)
10.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Price Forecast by Type (2022-2029)
10.4 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Forecast by Application (2022-2029)
10.5 Amyotrophic Lateral Sclerosis (ALS) Market Forecast Under COVID-19

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Data Source

List of Tables and Figures

Figure Amyotrophic Lateral Sclerosis (ALS) Product Picture
Table Global Amyotrophic Lateral Sclerosis (ALS) Sales and CAGR (%) Comparison by Type
Table Profile of Riluzole
Table Profile of Edaravone (Radicava)
Table Profile of Others
Table Amyotrophic Lateral Sclerosis (ALS) Consumption (Sales) Comparison by Application (2017-2029)
Table Profile of Hospital
Table Profile of Drugs Store
Table Profile of Others
Figure Global Amyotrophic Lateral Sclerosis (ALS) Market Size (Revenue) and CAGR (%) (2017-2022)
Figure United States Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Europe Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Germany Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure UK Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure France Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Italy Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Spain Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Russia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Poland Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure China Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Japan Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure India Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Malaysia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Singapore Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Philippines Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Indonesia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Thailand Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Vietnam Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Colombia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Nigeria Amyotrophic Lateral Sclerosis (ALS) Revenue and Growth Rate (2017-2022)
Figure Global Amyotrophic Lateral Sclerosis (ALS) Sales Status and Outlook (2017-2029)
Table Global Amyotrophic Lateral Sclerosis (ALS) Sales by Player (2017-2022)
Table Global Amyotrophic Lateral Sclerosis (ALS) Sales Share by Player (2017-2022)
Figure Global Amyotrophic Lateral Sclerosis (ALS) Sales Share by Player in 2021
Table Amyotrophic Lateral Sclerosis (ALS) Revenue by Player (2017-2022)
Table Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Player (2017-2022)
Table Amyotrophic Lateral Sclerosis (ALS) Price by Player (2017-2022)
Table Amyotrophic Lateral Sclerosis (ALS) Gross Margin by Player (2017-2022)
Table Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base Distribution and Sales Area by Player
Table Amyotrophic Lateral Sclerosis (ALS) Product Type by Player
Table Mergers & Acquisitions, Expansion Plans
Figure Amyotrophic Lateral Sclerosis (ALS) Industrial Chain Analysis
Table Key Raw Materials Suppliers and Price Analysis
Figure Market Concentration Rate of Raw Materials
Table Downstream Buyers
Figure Manufacturing Cost Structure Analysis
Table Key Raw Materials Introduction of Amyotrophic Lateral Sclerosis (ALS)
Figure Price Trend of Key Raw Materials
Figure Global COVID-19 Status Overview
Table Influence of COVID-19 Outbreak on Amyotrophic Lateral Sclerosis (ALS) Industry Development
Table AZTherapies Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table AZTherapies Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure AZTherapies Revenue and Growth Rate
Figure AZTherapies Revenue Market Share 2017-2022
Table Sanofi/Covis Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Sanofi/Covis Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Sanofi/Covis Revenue and Growth Rate
Figure Sanofi/Covis Revenue Market Share 2017-2022
Table Biogen Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Biogen Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Biogen Revenue and Growth Rate
Figure Biogen Revenue Market Share 2017-2022
Table Orphazyme Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Orphazyme Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Orphazyme Revenue and Growth Rate
Figure Orphazyme Revenue Market Share 2017-2022
Table Samus Therapeutics Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Samus Therapeutics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Samus Therapeutics Revenue and Growth Rate
Figure Samus Therapeutics Revenue Market Share 2017-2022
Table Orion Pharma Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Orion Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Orion Pharma Revenue and Growth Rate
Figure Orion Pharma Revenue Market Share 2017-2022
Table Clene Nanomedicine Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Clene Nanomedicine Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Clene Nanomedicine Revenue and Growth Rate
Figure Clene Nanomedicine Revenue Market Share 2017-2022
Table Novartis Pharmaceuticals Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Novartis Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Novartis Pharmaceuticals Revenue and Growth Rate
Figure Novartis Pharmaceuticals Revenue Market Share 2017-2022
Table Revalesio Corporation Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Revalesio Corporation Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Revalesio Corporation Revenue and Growth Rate
Figure Revalesio Corporation Revenue Market Share 2017-2022
Table Amylyx Pharmaceuticals Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Amylyx Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Amylyx Pharmaceuticals Revenue and Growth Rate
Figure Amylyx Pharmaceuticals Revenue Market Share 2017-2022
Table Gilead Sciences Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Gilead Sciences Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Gilead Sciences Revenue and Growth Rate
Figure Gilead Sciences Revenue Market Share 2017-2022
Table Biohaven Pharmaceuticals Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Biohaven Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Biohaven Pharmaceuticals Revenue and Growth Rate
Figure Biohaven Pharmaceuticals Revenue Market Share 2017-2022
Table Novus Therapeutics Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Novus Therapeutics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Novus Therapeutics Revenue and Growth Rate
Figure Novus Therapeutics Revenue Market Share 2017-2022
Table TikoMed AB/Neuregenix Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table TikoMed AB/Neuregenix Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure TikoMed AB/Neuregenix Revenue and Growth Rate
Figure TikoMed AB/Neuregenix Revenue Market Share 2017-2022
Table Annexon Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Annexon Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Annexon Revenue and Growth Rate
Figure Annexon Revenue Market Share 2017-2022
Table PTC Therapeutics/ Dainippon Sumitomo Pharma Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table PTC Therapeutics/ Dainippon Sumitomo Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure PTC Therapeutics/ Dainippon Sumitomo Pharma Revenue and Growth Rate
Figure PTC Therapeutics/ Dainippon Sumitomo Pharma Revenue Market Share 2017-2022
Table Alexion Pharmaceuticals Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Alexion Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Alexion Pharmaceuticals Revenue and Growth Rate
Figure Alexion Pharmaceuticals Revenue Market Share 2017-2022
Table Cytokinetics/Astellas Pharma Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Cytokinetics/Astellas Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Cytokinetics/Astellas Pharma Revenue and Growth Rate
Figure Cytokinetics/Astellas Pharma Revenue Market Share 2017-2022
Table GlaxoSmithKline Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table GlaxoSmithKline Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure GlaxoSmithKline Revenue and Growth Rate
Figure GlaxoSmithKline Revenue Market Share 2017-2022
Table Apellis Pharmaceuticals Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Apellis Pharmaceuticals Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2017-2022)
Figure Apellis Pharmaceuticals Revenue and Growth Rate
Figure Apellis Pharmaceuticals Revenue Market Share 2017-2022
Table Aquestive Therapeutics Profile
Table Amyotrophic Lateral Sclerosis (ALS) Product Profiles, Application and Specification
Table Aquestive

First Name *

Last Name

Country *

E-mail *

Contact No *

Company Name*

Job Title*

Comments

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Have a Question?

EMAIL US

RELATED PRODUCTS

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

View All New Reports

Global Freckle-removing Medical and Beau.. The global market for Freckle-removing Medical and Beauty Eq..

Global Wall Mounted Sinks Market Growth .. The sink is a trough-shaped appliance used to receive kitche..

Global Peripheral Imaging Catheter Marke.. The Peripheral Imaging Catheter's unique design provides exc..

Global Hemostatic Valves and Accessories.. Haemostatic valve prevents blood reflux when a catheter is i..

Global Liver Cancer Treatment Drug Marke.. The global market for Liver Cancer Treatment Drug is estimat..

Global Hypertensive Heart Disease Drug M.. The global market for Hypertensive Heart Disease Drug is est..

Global Urinary Incontinence Drug Market .. The global market for Urinary Incontinence Drug is estimated..

Global Pet Antibiotic Market Growth 2022.. The global market for Pet Antibiotic is estimated to increas..

Global Hemorrhagic Disease Detection Mar.. The global market for Hemorrhagic Disease Detection is estim..

Global Cell Dissociation Solution Market.. The global market for Cell Dissociation Solution is estimate..

Global Cell Detachment and Dissociation .. The global market for Cell Detachment and Dissociation Solut..

Global Cell Detachment Solution Market G.. The global market for Cell Detachment Solution is estimated ..

CUSTOM RESEARCH

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

LEARN MORE